Table 1 Outcomes of clinical trials of CAR T-cells presented at ASH 2024
From: Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024
Targets | NCT number | Source | Dose (10e6/kg) | Patients (n) | CR (n) | Side effects | ||
|---|---|---|---|---|---|---|---|---|
CRS (grade) | ICANS (grade) | Others | ||||||
CD123 | NCT04318678* | auto | 3 | 3 | NR | G 2, n = 3 | NR | NR |
10 | 3 | NR | G 4–5, n = 3 | IEC-HS, n = 3 | ||||
CD33 | NR | auto | 0.062–0.615 | 12 | 5 | G 1, n = 9; G 2, n = 1 | n = 0 | liver function damage, n = 4; sepsis, n = 2 |
CLL1(CD371) | NCT06017258 | auto | 0.3 | 2 | 2 | G 3–4, n = 1; G 1–2, n = 1 | G 3, n = 1 | DLT, n = 2 |
auto | 0.03 | 3 | 1 | G 3–4, n = 1; G 1–2, n = 2 | DLT, n = 1 | |||
ChiCTR2000041054†| auto | NR | 20 w/ EMDs | 13 | NR | NR | NR | |
27 w/o EMDs | 22 | |||||||
NR‡ | healthy donor | 3 | 3 | 2 | G 3, n = 2 | G1, n = 1 | NR | |
CD19 | NCT03896854§ | auto | 5–20 | 10 | 6 | G 1∼2, n = 8;G 3, n = 1 | NR | neutropenia or thrombocytopenia: G3, n = 3; G4, n = 7; G 1 liver dysfunction, n = 1; hypertension, n = 1 |
IL-1RAP | NCT06281847 | auto | 0.1, 0.5, 1, 5, 10 | NR | NR | NR | NR | NR |